Tenoxicam-induced Fixed Drug Eruption Confirmed by Patch Testing

Akin Cakici O., UZUNÇAKMAK T. K., SALMAN A.

Asthma Allergy Immunology, vol.23, no.2, pp.180-182, 2025 (ESCI, Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 2
  • Publication Date: 2025
  • Doi Number: 10.21911/aai.2025.729
  • Journal Name: Asthma Allergy Immunology
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.180-182
  • Keywords: Fixed drug eruption, patch testing, tenoxicam
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Tenoxicam has been associated with cutaneous adverse reactions, and it is categorized as a non-steroidal anti-inflammatory drug (NSAID) within the oxicam class. Herein, we report a patient with tenoxicam-induced fixed drug eruption (FDE) confirmed with patch testing. FDE is a delayed type hypersensitivity reaction frequently caused by antimicrobials and NSAIDs. Cross-reactivity may occur among the oxicams, and alternative medications should be carefully selected. This report highlights the importance of patch testing in identifying the causal drug in FDE, and the rise in awareness of tenoxicam as a potential trigger.